Table 1.
Tissue specificity |
Cre line | Expression Temporal |
Expression Spatial |
Efficiency | Laboratory source |
Original reference |
Potential caveats |
---|---|---|---|---|---|---|---|
Cardiac constitutive |
Alpha MHC | E10.5 | CMs | 70% excision in adult CMs |
Abel | [34] | - |
Alpha MHC | Low levels E8.0–E10.0 |
CMs | 70–80% excision by 3 weeks |
Schneider | [35] | High expression level leads to DCM |
|
Beta MHC | E12.5 | CMs | 70% excision by E17.5 |
Yutzey and Molkentin |
[66] | Expressed in somites and soleus muscle |
|
Nkx2.5 | E8.0-E8.5 | CMs | 88% excision in adult CMs |
Olson | [37] | - | |
Nkx2.5 | E7.75–E8.0 | CMs, pharyngeal endoderm |
High | Harvey | [38] | - | |
Nkx2.5 | E7.5 | CMs | 100% excision by PI |
Schwarz | [39] | Development of heart abnormalities |
|
cTnT | E7.5–E10.5 | CMs | High | Hogun | [42] | Breeding problems in older mice |
|
XMLC2 | E7.5– adulthood |
CMs | High | Mohun | [44] | - | |
MLC2v | E8.5 | Ventricular CMs | Low | Chen | [45] | - | |
Inducible cardiac |
MerCreMer-Alpha MHC |
N/A | CMs | >80% excision after 5 days |
Molkentin | [48] | Cre toxicity observed at high levels |
MerCreMer-cTnT | N/A | CMs | High | Cai | [55] | - | |
Tet-TnT | N/A | CMs | Not reported | Zhou | [56] | - | |
Constitutive skeletal |
HSA | E9.5 | Skeletal muscle, some evidence in heart |
High | Melki | [57] | Low level expression in the heart |
Myo | E8.5 | Skeletal muscle lineage | >90% excision | Olson | [60] | - | |
Inducible skeletal |
HSA-MerCreMer | - | Skeletal muscle, some evidence in heart |
High | Esser | [58] | Low level expression in the heart |
HSA-Tet | - | Skeletal muscle | Not reported | Monks | [59] | - | |
CreRT2 lines | - | Various | Lepper | [61] | - |
CMs: cardiomyocytes, E: embryonic day, MHC: myosin heavy chain, Nkx2.5: Nk2 homeobox 5, cTnT: cardiac troponin T, XMLC2: Xenopus myosin light chain 2, MLC2V: myosin light chain 2 ventricular, MerCreMer: mutated estrogen receptor, Dox: doxycycline, HSA: human alpha skeletal actin, DCM: dilated cardiomyopathy